The COVID 19 pandemic demonstrated that Europe can move fast, take risk, and deliver world class vaccines when political will, science and capital are aligned. Treating vaccines as strategic assets, backed by sustained political and financial support, will be key to maintaining Europe’s long-term investment in public health and innovation.
The rollercoaster ride stopps and danish IO Biotech goes bust
Latest NewsThe Copenhagen-based cancer immunotherapy company IO Biotech has come to an abrupt end, marking one of the more sobering recent failures in Europe’s mid-cap biotech segment. Founded in 2019, the company had sought to position itself at the forefront of therapeutic cancer vaccines, but a decisive clinical and regulatory setback ultimately proved insurmountable.
French AI: 20 million funding for Generare to find better data in nature
Latest NewsFrench Generare, founded in 2023, is positioning itself at the intersection of synthetic biology and artificial intelligence by tackling what many in the sector now see as a fundamental bottleneck: the lack of genuinely novel molecular data.
Lilly moves deeper into sleep medicine with up to $7.8 billion Centessa deal
Latest NewsEli Lilly has agreed to acquire UK-based Centessa Pharmaceuticals in a deal worth up to $7.8 billion, giving the pharma giant a high-profile entry into one of biotech’s most closely watched neuroscience fields: orexin biology. The companies announced a definitive agreement on March 31, 2026.
Where Life Science Scales in Basel
slider, Sponsored PublicationsThe Basel region is one of the world’s leading life-science clusters. Pharmaceutical companies, biotech firms and research institutions benefit from a unique combination of talent, infrastructure and international collaboration. As the industry continues to grow, the demand for scalable laboratory and office environments within this innovation ecosystem is increasing.
Something of a shopping spree: Novartis to acquire US-based Excellergy for up to $2bn
Latest NewsNovartis is back on the acquisition trail, agreeing to buy California-based Excellergy for up to $2bn. The antibody Exl-111 is intended to strengthen its allergy pipeline and go beyond the current standard of care. The deal is part of a broader string of acquisitions aimed at systematically expanding the group’s innovation base.
Europe’s pivotal choice: Vaccination is health security
Latest News, OpinionThe COVID 19 pandemic demonstrated that Europe can move fast, take risk, and deliver world class vaccines when political will, science and capital are aligned. Treating vaccines as strategic assets, backed by sustained political and financial support, will be key to maintaining Europe’s long-term investment in public health and innovation.
10 European Startups to watch in 2026
Background, Latest NewsTen young European biotechs are heading into 2026 with the kind of momentum that can quickly turn promising science into defining data: first clinical entries, platform-to-pipeline transitions, and funding rounds large enough to accelerate execution. Some are pushing new modalities into hard disease areas, while others are compressing discovery timelines and expanding what’s druggable. What they all share is a clear momentum that makes them especially worth following this year.
Ysios Capital launches InceptionBio: €100m for Spanish biotech spinouts
Latest NewsSpanish VC firm Ysios Capital has unveiled InceptionBio, a €100 million fund dedicated to boosting Spanish biotech innovation. The initiative targets company creation from top-tier research, backed by public-private partnerships.
The European CDMO Model, Powering Biologics Innovation
Sponsored PublicationsEurope continues to play a pivotal role in the global biologics landscape, combining scientific excellence, regulatory maturity and a strong industrial foundation.
EIF starts €15bn fund-of-funds for scaling European tech companies
Latest NewsThe European Investment Fund has launched a new fund of funds with a target volume of €15 billion to strengthen growth financing in Europe’s technology sector. The programme is considered the largest of its kind in Europe to date and is aimed at around 100 late-stage venture capital funds.